Teriflunomide is a pyrimidine synthesis inhibitor used in the treatment of multiple sclerosis that has in rare instances been associated with liver toxicity, though there are few documented cases. Here, we report a case of probable teriflunomide-induced liver injury as assessed for causality using the updated RUCAM. The liver injury occurred approximately nine months after teriflunomide initiation and improved with discontinuation of the drug and treatment with cholestyramine.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9217622 | PMC |
| http://dx.doi.org/10.1155/2022/6331923 | DOI Listing |
Publication Analysis
Top Keywords
assessed causality
8
causality updated
8
updated rucam
8
liver injury
8
case delayed
4
delayed hepatic
4
hepatic injury
4
injury associated
4
associated teriflunomide
4
teriflunomide assessed
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!